The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

Inclusion Criteria: * HIV-infected * VL suppressed \<40c/ml for at least 6 months, blips are allowed * planned to have bariatric surgery (gastric bypass or gastric sleeve) * Able to sign informed consent * Age \> or equal to 18 years * Using doravirine for at least 4 weeks prior to BS with VL \< 40 copies/mL prior to the surgery Exclusion Criteria: * History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation * Requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine * Has significant hypersensitivity or other contraindication to doravirine * Creatinine clearance \<40 ml/min * Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C) * Pregnancy or planning to be pregnant during first 6 months postbariatric surgery.